Source-grounded facts extracted from RenovoRx, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
RenovoRx, Inc. reported the first quarter ended March 31, 2026 results: revenue $563,000.
“herein by reference. --- EX-99.1 (EX-99.1) --- EX-99.1 RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMPTM Therapy”
RenovoRx, Inc. reported fiscal year ended December 31, 2025 results: revenue $1.1 million.
“For the year ending December 31, 2025, the Company generated $1.1 million in revenue from RenovoCath sales, driven by both new cancer centers adopting the device and repeat orders from existing customers.”
RenovoRx, Inc. issued 5,319,392 shares of Common Stock of warrant to 15 accredited investors or qualified institutional buyers for exercise price equal to $1.751 per share for the Institutional Investors and $1.9326 for the Insiders.
“product sales) for any calendar quarter in a quarterly or annual report. The Milestone Warrants will entitle the holder to purchase Warrant Shares at an exercise price equal to $1.751 per share for the Institutional Investors and $1.9326 for the Insiders. The Milestone Warrants are subject to a beneficial ownership limitation, preventing any holder from”
RenovoRx, Inc. issued 2,200,000 shares of Common Stock of warrant to 15 accredited investors or qualified institutional buyers for price per share of Common Stock being sold to the Institutional Investors in the Offering, minus $0.0001.
“Securities Purchase Agreement, in connection with the Offering, the Company sold to the Investors an aggregate of: (i) 8,438,790 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (the “Common Stock”), (ii) pre-funded warrants to purchase an aggregate of 2,200,000 shares of Common Stock (the “Pre-Funded Warrants”) and (iii)”
RenovoRx, Inc. issued 8,438,790 shares of common stock to 15 accredited investors or qualified institutional buyers for $0.938 per Share.
“and Milestone Warrants are referred to herein as the “Warrant Shares.” The purchase price paid by the Institutional Investors for each Share and related Milestone Warrant was $0.938. To comply with Nasdaq Stock Market rules, the purchase price paid by the Insiders for each Share and related Milestone Warrant was $1.0288. The Securities Purchase Agreement”
RenovoRx, Inc. entered into Securities Purchase Agreement with 15 accredited investors or qualified institutional buyers valued at aggregate gross proceeds of approximately $10 million (effective 2026-03-17).
“On March 17, 2026, RenovoRx, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) in connection with a private placement offering by the Company (the “Offering”) to 15 accredited investors or qualified institutional buyers (the “Investors”), five of whom are directors, officers or employees of the Company (the “Insiders”) and the remaining are non-affiliated institutional investors (the “Institutional Investors”).”
RenovoRx, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“December 31, 2025, RenovoRx, Inc., a Delaware corporation (the “Company”) received a deficiency notice from The Nasdaq Stock Market (“Nasdaq”) informing the Company that its common stock, par value $0.0001 per share (the “Common Stock”), failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the Common Stock for the 32 consecutive business days prior to the date of the notice from Nasdaq. Nasdaq’s notice has no immediate effect on the listing of the Common Stock on Th”
Baker Tilly US, LLP resigned as auditor of RenovoRx, Inc..
“eceived a letter from Baker Tilly US, LLP (“BT”), notifying the Committee that BT has decided to resign as the independent registered public accounting firm of the Company effective immediately following the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, which is expected to be filed in August 2024. The Company is currently in the process of interviewing other accounting firms to replace BT as the Company’s independent registered public accounting firm upon the effectiveness of BT’s resignation. The reports of BT on the Company’s financial statements for the fiscal years ended December 31, 2023 and 2022,”
RenovoRx, Inc. entered into Subscription Agreements with approximately 170 accredited investors (effective 2024-04-04).
“On April 4, 2024, RenovoRx, Inc. (the “Company”) entered into a series of definitive subscription agreements (the “Subscription Agreements”) in connection with a private placement offering by the Company (the “Offering”) to approximately 170 accredited investors (the “Investors”).”
Leesa Gentry was appointed as Chief Clinical Officer at RenovoRx, Inc..
“On February 22, 2024, the board of directors (the “Board”) of RenovoRx, Inc., a Delaware corporation (the “Company”), appointed Leesa Gentry, the Company’s former Senior Vice President of Clinical Operations, to the position of Chief Clinical Officer of the Company.”
RenovoRx, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“February 21, 2024, the Company received a written notice (the “Notice”) from Nasdaq that the Company had, as of the date of the Notice, failed to meet the Minimum Stockholders’ Equity Requirement and that Nasdaq would commence delisting proceedings against the Company unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Hearing Panel”). The Company plans to request a hearing, which request will stay any delisting or suspension action by the Nasdaq staff at least pending the issuance of the Hearing’s Panel decision and the expiration of any extension that may be gr”
Leesa Gentry was appointed as Chief Clinical Officer at RenovoRx, Inc..
“On February 22, 2024, the Company’s board of directors (the “Board”), by unanimous written consent to action, appointed Leesa Gentry, the Company’s current Senior Vice President of Clinical Operations, to the position of Chief Clinical Officer of the Company, effective March 1, 2024.”
Angela Gill Nelms resigned as Chief Operating Officer at RenovoRx, Inc..
“On February 16, 2024, Angela Gill Nelms provided written notice to the Company of her resignation as the Company’s Chief Operating Officer, effective March 1, 2024.”
Ronald B. Kocak was appointed as Vice President, Controller and Principal Accounting Officer at RenovoRx, Inc..
“On February 8, 2024, the Company’s board of directors (the “Board”), at the recommendation of the audit and compensation committees of the Board, appointed Ronald B. Kocak, CPA, CGMA, the Company’s current Vice President and Controller, to the position of Vice President, Controller and Principal Accounting Officer.”
James Ahlers resigned as Chief Financial Officer at RenovoRx, Inc..
“On February 5, 2024, James Ahlers provided written notice to RenovoRx, Inc. (the “Company”) of his resignation as the Company’s Chief Financial Officer, effective immediately.”
RenovoRx, Inc. entered into Placement Agent Agreement with Paulson Investment Company, LLC (effective 2023-11-14).
“On November 14, 2023, in connection with the Offering, the Company entered into a placement agent agreement, a copy of which is filed as Exhibit 10.4 to this Current Report on Form 8-K (the “Placement Agent Agreement”) with Paulson Investment Company, LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the Company’s placement agent in connection with the Offering.”
RenovoRx, Inc. entered into Subscription Agreements with 92 accredited investors valued at $6,111,695 (effective 2024-01-26).
“On January 26, 2024, RenovoRX, Inc. (the “Company,” “us,” “we,” or “our”) entered into a series of subscription agreements, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K (the “Subscription Agreements”), in connection with a private placement offering to 92 accredited investors (the “Investors”), which was also closed on January 26, 2024, and pursuant to which we raised aggregate gross proceeds of $6,111,695 (the “Offering”).”
RenovoRx, Inc. shareholders approved Approval of issuance of shares of Common Stock in non-public offerings (Equity Issuance Proposal) at the 2023-12-15 meeting.
“The following is a tabulation of the votes with respect to the Equity Issuance Proposal, which was approved by the Company’s stockholders: For Against Abstain 4,747,833 336,779 3,200”
RenovoRx, Inc.: Reduced stockholder meeting quorum requirement from a majority to one-third of voting power and enhanced procedural mechanics for stockholder nominations and proposals, including Universal Proxy Rule compliance (effective 2023-09-07).
“On September 7, 2023, in connection with the adoption of Rule 14a-19 (the “Universal Proxy Rules”) under the Securities Exchange Act of 1934, as amended, certain recent changes to the Delaware General Corporation Law (the “DGCL”), and a periodic review of the bylaws of RenovoRx, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) adopted amended and restated bylaws (the “Amended and Restated Bylaws”), effective immediately”
RenovoRx, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“August 21, 2023, RenovoRx, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as of August 18, 2023, the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company’s stockholders’ equity of $1,188,000 as reported in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2023 was below the required minimum of $2.5 million, and because, as of June 30”
RenovoRx, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-08 meeting.
“Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 7,463,474 22,982 1,257 0 The stockholders ratified the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
RenovoRx, Inc. shareholders approved Election of Directors at the 2023-06-08 meeting.
“Proposal 1: Election of Directors Name of Director For Withheld Broker Non-Votes Ramtin Agah, M.D. 5,094,179 19,343 2,374,191 Shaun R. Bagai 5,094,179 19,343 2,374,191 David Diamond 5,107,063 6,459 2,374,191 Kirsten Angela Macfarlane 5,106,837 6,685 2,374,191 Laurence J. Marton, M.D. 5,068,635 44,887 2,374,191 Una S. Ryan, O.B.E., Ph.D., D.Sc. 5,053,096 60,426 2,374,191 Robert J. Spiegel, M.D., FACP 5,013,634 99,888 2,374,191 Each director nominee was duly elected to serve until the 2024 Annual Meeting of Stockholders and until their successor is duly elected and qualified, subject to their earlier resignation or removal.”
RenovoRx, Inc. reported the first quarter ended March 31, 2023 results: net income $3.3 million.
“RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced financial results for the first quarter ended March 31, 2023.”
Robert Spiegel was appointed as independent director at RenovoRx, Inc..
“Effective as of April 25, 2023, the Board of Directors of RenovoRx, Inc. (the “Company”) appointed Robert Spiegel, M.D., FACP, to its Board of Directors as an independent director”
RenovoRx, Inc. entered into Placement Agreement with Roth Capital Partners, LLC (effective 2023-03-30).
“Roth Capital Partners, LLC (the “ Placement Agent ”) acted as the exclusive placement agent for the Offerings, pursuant to a placement agency agreement (the “ Placement Agreement ”), dated March 30, 2023, by and between the Company and the Placement Agent.”
RenovoRx, Inc. entered into Securities Purchase Agreement with a certain institutional investor valued at approximately $5.00 million (effective 2023-03-30).
“On March 30, 2023, RenovoRx, Inc. (the “ Company ,” “ we ” or “ us ”) entered into a securities purchase agreement (“ Securities Purchase Agreement ”) with a certain institutional investor (“ Purchaser ”).”
RenovoRx, Inc. reported year ended December 31, 2022 results: net income Net loss was $9.9 million for the ended December 31, 2022, EPS Net loss per share, basic and diluted were ($1.09) for the year ended December 31, 2022.
“● Net loss was $9.9 million for the ended December 31, 2022, compared to net loss of $6.3 million for year ended December 31, 2021. ● Net loss per share, basic and diluted were ($1.09) for the year ended December 31, 2022, compared to ($1.21) for the year ended December 31, 2021.”
RenovoRx, Inc. reported the quarter ended September 30, 2022 results: net income $2.1 million.
“Net loss was $2.1 million for the quarter ended on September 30, 2022, compared to a net loss of $1.5 million for Q3 ended September 30, 2021.”
Angela Gill Nelms was appointed as Chief Operating Officer at RenovoRx, Inc..
“The Board of Directors of RenovoRx, Inc. (the “Company”) has appointed Ms. Angela Gill Nelms, age 47, as Chief Operating Officer, effective September 19, 2022, her start date with the Company.”
James Ahlers was appointed as Chief Financial Officer, Secretary and Treasurer at RenovoRx, Inc..
“The Company’s Board of Directors has appointed Mr. James Ahlers, age 58, as Chief Financial Officer, Secretary and Treasurer, as of July 15, 2022.”
Christopher J. Lehman resigned as Chief Financial Officer at RenovoRx, Inc..
“Christopher J. Lehman notified RenovoRx, Inc. (the “Company”) of his decision to resign as Chief Financial Officer, effective July 15, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.